Tomato diet shows promise for fatty liver relief
NCT ID NCT06389851
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether a diet rich in tomatoes could improve liver health, gut function, and blood sugar in people with non-alcoholic fatty liver disease (NAFLD). Eighty participants either ate a tomato-free diet or one with added tomatoes and sauce for six weeks. Researchers measured liver fat, fibrosis, inflammation, and gut bacteria to see if tomatoes made a difference.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tomato-enriched diet
- What this could lead to
- If it works, this could point toward a simple dietary change to help manage fatty liver disease and related health issues.
- What could go wrong
- This is a small, completed study with no phase designation, so results may not be conclusive or widely applicable. Dietary interventions can be hard to separate from other lifestyle factors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
80 people
The number who actually took part.
- Started
-
May 2024
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with BMI≤30; * Diagnosis of hepatic steatosis, formulated on the basis of criteria Exclusion Criteria: * Patients with BMI \> 30; * Presence of any pathology that could influence the presence of steatosis apart from the pathologies that represent inclusion criteria; * Pregnancy or breastfeeding; * Serious medical conditions that may compromise participation in the trial; * People following a special diet.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Irccs Saverio de Bellis
Castellana Grotte, BARI, 70013, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can talk therapy and mindfulness shrink a fatty liver?
- Machine learning sifts through IBS symptoms to find hidden patient types
- A smartphone app may help curb the silent march of fatty liver disease toward cirrhosis
- AI and blood biomarkers could catch hidden liver damage
- A protein supplement may fight fatty liver in teens
- Can a single pill tackle both fatty liver and diabetes?